FDA approves new pancreatic cancer drug shown to extend survival

The FDA approved Rasonque (daraxonrasib), a new oral drug that extends survival by significantly reducing death risk in adults with metastatic pancreatic adenocarcinoma, based on positive late-stage trial results.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.